U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H35F3O6
Molecular Weight 500.5477
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of TRAVOPROST

SMILES

CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC2=CC(=CC=C2)C(F)(F)F

InChI

InChIKey=MKPLKVHSHYCHOC-AHTXBMBWSA-N
InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1

HIDE SMILES / InChI

Description

(+)-Fluprostenol is the optically active enantiomer of fluprostenol. It is a potent and highly selective prostaglandin F2-alpha (FP) receptor agonist. (+)-Fluprostenol corrected corpora lutea persistence in the mares without significant clinical side effects. It was also an effective at inducing parturition in alpacas.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
1.4 nM [EC50]
49.9 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TRAVATAN Z
Primary
Unknown
Preventing
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
0.018 ng/mL
1 drop 1 times / day multiple, ocular
FLUPROSTENOL plasma
Homo sapiens
0.049 ng/mL
1 drop 1 times / day multiple, ocular
FLUPROSTENOL plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
0.039 ng × h/mL
1 drop 1 times / day multiple, ocular
FLUPROSTENOL plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
45 min
1 drop 1 times / day multiple, ocular
FLUPROSTENOL plasma
Homo sapiens
31.8 min
1 drop 1 times / day multiple, ocular
FLUPROSTENOL plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
20%
FLUPROSTENOL plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended dosage is one drop in the affected eye(s) once daily in the evening. TRAVATAN Z® (travoprost ophthalmic solution) should not be administered more than once daily
Route of Administration: Topical
In Vitro Use Guide
Travoprost stimulated the contraction of isolated non-pregnant female rat uterus in a concentration-dependent manner with the agonist potency EC(50)=1.3+/-0.07 nM